She downloaded the app on a Sunday afternoon, somewhere between swapping out the laundry and answering one last Slack message. The promise was irresistible: “AI‑powered, personalized menopause support.” For the first few weeks, it felt true. The app anticipated her questions, surfaced articles that made sense of her symptoms, and pinged her at just the right moment to log another night of fractured sleep. Then the quarter changed, a big project landed, her teenager started applying to college—and the “personalization” froze in place. The prompts kept coming, but they were tuned to the version of her life that existed in week two, not week ten.

Why AI Personalization in Women’s Health Often Breaks Down in Real Life

This is the quiet reality underneath a lot of AI hype in women’s health right now. Platforms are racing to add machine learning to symptom prediction, cycle insights, and care recommendations. Marketing language has shifted almost overnight: “AI‑driven,” “AI‑powered,” “AI‑personalized.” But when you zoom in on where the retention crisis actually lives—whether women stay engaged past the first 30–90 days—the impact is far less impressive. The technology is getting smarter about the data in front of it, while staying largely blind to the context that shapes whether a woman can actually act on that data.

The Women’s Health Retention Problem Starts After the First 30 to 90 Days

Most of what passes for AI‑personalization today is product‑layer intelligence laid on top of yesterday’s engagement models. The system knows your cycle phase or hormone regimen, but not that you are in the middle of a performance review cycle, caring for a parent, or renegotiating intimacy in a long‑term relationship. It can optimize which article or tip to show next, but it still operates on a fixed schedule of nudges and checklists, assuming more information will translate into more engagement. When capacity drops—because of workload, stress, grief, or simple midlife fatigue—the app doesn’t adjust its expectations. It just keeps pushing.

This pattern isn’t unique to one app. Across digital health, engagement drop‑off is well documented: most users discontinue health apps within the first 30 to 90 days, and very few platforms achieve meaningful long‑term retention. That might be tolerable for a step‑counting experiment or a short‑term diet program. In women’s health, where fertility, perimenopause, menopause, and chronic hormonal conditions unfold over months and years, it is catastrophic. The very journeys that most need sustained support are the ones least well served by engagement systems built for short‑cycle use.

The default pattern in digital health is 30–90 days of enthusiasm followed by quiet abandonment; Metis exists to help women’s health platforms design for everything that’s supposed to happen after day 91.

What AI‑Native Customer Success Means in Women’s Health

AI‑Native Customer Success starts from a different premise. Instead of asking, “How do we use AI to make our product smarter?” it asks, “How do we use AI to understand and support the way women actually move through long, identity‑shaping health journeys?” In that model, AI doesn’t just crunch symptoms; it listens to engagement signals, senses when someone is drifting, and helps decide when to offer less, not more. It treats capacity, context, and connection as first‑class inputs, not afterthoughts—which is exactly what’s missing in most of today’s “personalized” women’s health experiences.

Three Reasons Current AI Misses the Real Engagement Problem

If you look closely, most AI in women’s health today is pointed at the wrong part of the problem. It is very good at making sense of what’s happening inside the app and much less interested in what’s happening inside a woman’s life. Three patterns show up again and again.

1. Data Without Context

Models ingest cycle length, symptom intensity, medication changes, even sleep and heart‑rate variability. But those streams are rarely paired with what actually shapes capacity: workload spikes, caregiving demands, relationship stress, financial pressure, or major life transitions. The system may correctly infer that hot flashes are improving, but it has no idea that her cognitive bandwidth is collapsing under a new role at work. To the model, she looks “better.” To her, she feels more overwhelmed than ever.

2. More Prompts, Worse Timing

Once AI gets involved, the default move is to increase the number of “smart” touchpoints—more personalized tips, more perfectly segmented campaigns, more notifications tuned to micro‑behaviors. But if those touchpoints still land at the wrong moments, they register as noise, not support. The woman in back‑to‑back meetings doesn’t need a beautifully optimized article recommendation; she needs the system to understand there is no space right now and to adjust expectations accordingly.

3. Static Journeys Disguised as Personalization

The content may change based on symptoms, but the underlying journey still assumes a linear path: onboard, engage, succeed. There is little room for relapse, regression, or the cyclical nature of hormonal and life stages. When a woman stops engaging, the system’s only interpretation is “lost interest” or “poor fit,” not “something in her life or identity shifted and our model of her journey is now wrong.” In that world, AI becomes a more efficient way to push a misaligned journey rather than a way to notice misalignment and respond.

What Changes When Customer Success Becomes AI‑Native

An AI‑Native Customer Success model turns that logic inside out. Instead of using AI primarily to decide what information to show next, it uses AI to understand how a woman is traveling through her health journey and whether she has the capacity to engage at all. The data doesn’t change; the questions you ask of it do.

In an AI‑native CS system, engagement signals sit alongside symptoms and labs as first‑class data. The platform watches for changes in logging cadence, completion patterns, response times, language in messages or surveys, and participation in community interactions—not as vanity metrics, but as indicators of how present or distant a woman feels from her own care. When those patterns shift, the system doesn’t just optimize the next tip; it asks, “Is she drifting? What might have changed in her world?” and adjusts its posture accordingly.

Support also becomes explicitly capacity‑sensitive. Imagine the same midlife woman from Sunday afternoon. In month one, she is logging diligently, reading articles, joining live sessions. In month three, her logging drops, she skips two sessions, and the words she uses in brief check‑ins tilt toward “exhausted” and “foggy.” A product‑only AI might double down on content about sleep hygiene and memory. An AI‑Native CS model reads those same signals as a potential capacity crash. It might temporarily reduce the volume of messages, surface a concise “here’s the one thing to focus on this week,” or route her into a short, human‑led check‑in that acknowledges the reality of her workload and offers permission to do less without “failing” the program.

Crucially, AI‑native CS uses intelligence to target human touch, not erase it. In women’s health, trust often crystallizes around a single conversation where a woman finally feels seen. The point of AI is to make those conversations more likely and better timed: to identify which women are at quiet inflection points, which cohorts are slipping into silent churn, and where a short, well‑framed human outreach could change the trajectory. The system’s job is not just to keep the app busy; it is to keep women in relationship with their health journey in ways that respect their changing capacity, identity, and life context.

Why This Matters Now for Femtech Platforms, Renewals, and Growth

In a different funding climate, all of this might have remained a product‑team headache: frustrating, but survivable. In 2026, it is a board‑level problem. Cheap capital is gone; growth has to be earned. Employer and payer buyers who signed women’s health contracts in 2022 and 2023 are now in renewal cycles, facing their own pressure to show that each benefit line item delivers outcomes and return on investment. Shorter contracts and annual portfolio reviews mean there is less room to hide engagement problems inside multi‑year deals.

At the same time, midlife and menopause have become focal points of both investment and expectation. Employers are announcing menopause benefits as part of their talent and retention strategies. Health plans are piloting midlife women’s health programs to reduce downstream costs. The story on the slide is that these benefits will keep experienced women in the workforce and healthier over time. That story only holds if women actually stay engaged with the platforms providing the care. In that context, shallow AI‑personalization is not just a UX flaw—it is a commercial liability.

When engagement systems fail, the impact cascades. Women lose access to consistent support in the middle of complex, identity‑shifting journeys. Employers and payers struggle to justify renewals in the absence of credible outcomes.

Platforms find themselves squeezed between rising expectations and engagement models that were never engineered for long‑term participation. AI‑Native Customer Success is not a nice‑to‑have upgrade in that environment; it is one of the few levers that can connect individual women’s lived experience to the retention and outcomes story leadership needs to tell.

In a previous article, I looked at how employer renewals and outcomes‑based contracts are exposing femtech’s engagement gap. This article focuses on a different angle: what today’s AI ‘personalization’ is missing about long women’s health journeys.

The Next Step: The Retention Reckoning and Metis Femtech’s Q4 Pilots

This article is one piece of a larger project I’m doing at Metis Femtech to name and address the engagement architecture gap in women’s health. The Q2 2026 Metis Femtech Intelligence Brief, The Retention Reckoning, goes deeper into how cheap capital masked a chronic retention crisis, why midlife women and menopause are the stress test for current models, and what an AI‑Native Customer Success approach looks like at the level of principles and system design. It’s written for founders, product leaders, Customer Success heads, and clinical leaders who know that “more AI in the product” hasn’t moved their engagement curves in the way they hoped.

For teams ready to experiment with AI‑native engagement in practice, I’m also running a small number of Q4 pilots with women’s health platforms. These include a 90‑day Midlife Retention Lab to surface and address silent churn in menopause programs, an Employer Renewal Shield that uses engagement intelligence to strengthen upcoming renewal stories, and an AI‑Native CS Blueprint for early‑stage femtech companies that want to design for long‑journey retention before they scale. The details live in the Q2 brief, but the core idea is simple: put AI where the real risk is—on how women are engaged and supported over time—and treat engagement as infrastructure, not an afterthought.

If you’re building or operating in women’s health and recognize pieces of your own platform in this description—the strong product, the early engagement, the quiet fall‑off after 90 days—this is the moment to re‑consider what “AI‑powered” should mean. Not just smarter insights, but smarter care for the relationship between women, their health journeys, and the systems that claim to support them.

Selected data points in this article draw on published research on digital health retention and digital health purchasing, including work by Nature Digital Medicine and Peterson Health Technology Institute. For a fuller source list and methodology, see the Sources & Methodology section of the Metis Femtech Q2 2026 Intelligence Brief, “The Retention Reckoning.”

About Metis Femtech Consultancy

Metis Femtech is a strategic advisory helping women’s health platforms solve the engagement and retention problems that threaten long-term growth. We work with founders, product leaders, and Customer Success teams to design for the full arc of women’s health journeys — not just the first 90 days. Learn more at metisfemtech.com.

The story goes like this: the D2C model was always fragile — dependent on paid acquisition, vulnerable to churn, and held together by cheap capital that made replacing lost users cheaper than retaining them. When funding contracted, that model broke. But femtech was already pivoting. Employer and payer contracts were the answer. B2B2C was the durable revenue model, the path to scale, the proof that women’s health technology had grown up.

The story is not wrong. The pivot is real. One of the sector’s most scaled B2B2C platforms now covers more than 17 million lives globally through employer benefit plans. The market is actively moving from volatile D2C models toward stable B2B corporate integration. These are real shifts.

What the story leaves out is this: the pivot imported the engagement problem. It didn’t solve it. It just changed the audience that would eventually notice.

That audience — employers, payers, and HR benefits leaders — is noticing now. And the mechanism forcing the issue is something femtech platforms have underestimated: the contract renewal cycle.

The Story Femtech Tells Itself About D2C and B2B2C

Before we get to the renewal crisis, it’s worth naming why the B2B2C pivot felt like a solution.

D2C femtech was visibly broken by 2022. Acquisition costs were high, churn was endemic, and retention metrics that had been obscured by a constant flow of replacement users became impossible to ignore once that flow slowed. The employer and payer channel looked like an escape hatch: larger contracts, stickier revenue, institutional credibility, and a buyer — the HR or Benefits leader — who wasn’t going to churn the way a consumer would.

What the pivot didn’t change was the underlying architecture. The platforms that moved into B2B2C brought their engagement models with them. Those models were built for acquisition, not for the sustained behavioral change that produces clinical outcomes. That distinction didn’t matter much in the early years of employer contracts. It matters now.

The PMPM Contract Structure That Hid Femtech’s Utilization Problem

To understand why employer renewals are the inflection point, you have to understand how most femtech platforms sold into the enterprise in the first place.

The dominant contract structure has been per member per month (PMPM) pricing. Under PMPM, an employer pays a fixed monthly fee based on their covered population — not their engaged one. A company covering 5,000 employees pays the same fee whether 500 of those employees actively use the platform or 50 do.

This matters because the utilization data for digital health point solutions has always been damaging, and PMPM pricing made it easy to avoid surfacing it. Industry benchmarks tell a clear story: most digital health solutions struggle to achieve even a 5 to 10 percent enrollment rate among eligible employees. Leading programs reach 20 to 30 percent. That means the average femtech platform, operating at baseline industry performance, is delivering meaningful engagement to fewer than one in ten of the employees an employer is paying to cover.

Under PMPM, this stays invisible. The invoice doesn’t change. The renewal conversation doesn’t require the vendor to explain the gap between covered lives and active users. The problem exists — it’s just not in the contract.

One benefits industry analyst put it plainly: per member per month contracts were a gift to digital health companies, particularly those struggling with utilization.

That gift is expiring.

Shorter Contracts, Tougher Renewals: The New Employer Expectations

Most employers are now reviewing their digital health vendor portfolios annually. The Peterson Health Technology Institute’s 2025 State of Digital Health Purchasing survey found that 73 percent of purchasers use short-term contracts of two years or less. The contract cycles that gave femtech platforms room to grow into their utilization claims are compressing.

More critically, what employers are asking at renewal has fundamentally shifted.

A major national health plan’s 2026 employer trends report is explicit: vendors are facing greater pressure to demonstrate measurable outcomes — not just rely on access or utilization metrics. The Business Group on Health, which represents major U.S. employers, issued direct purchasing guidance for 2025: Finance and Benefit teams should insist on outcomes-based contracts that require vendors to demonstrate improvement in health outcomes and deliver promised returns.

This is not future-state language. This is the guidance sitting in front of HR and Benefits leaders at large employers right now, as they approach renewal conversations with their femtech vendors.

The WTW survey data puts a number on the shift: nearly 80 percent of employers say they need to see a clear return on investment from their point solution partners. A venture capital principal advising digital health investments described what this looks like in practice: “I’m seeing a much higher bar for a two-year ROI. If point solutions don’t deliver, or if employees aren’t utilizing services, employers and EAPs are quickly moving on.”

ROI Benchmarks, Self‑Reported Outcomes, and the Validation Gap

One of the sector’s most cited B2B2C case studies offers the clearest benchmark for what a passing grade now looks like. It reports a 4.2x clinical and business return on investment, meaning payers saw more than four dollars of value for every dollar they spent, plus per‑member savings of about $4,600 — calculated as total savings divided by the number of participating members — through a major payer partnership. These numbers are real and they matter. They also reveal how high the bar has been set — and how few femtech platforms have the measurement infrastructure to produce equivalent claims.

It’s worth noting that the productivity and return-to-work figures in that case are self-reported by members. Sophisticated benefits buyers are already flagging this. Third-party validated outcomes — independently verified rather than vendor-curated — are becoming the next threshold. The Validation Institute, which independently verifies performance claims for healthcare solutions, reported significant growth in companies seeking validation in 2024, describing it as “a key differentiator for any company looking to win more business and be seen as a credible solution in the eyes of benefits buyers.” No femtech platforms appeared on their 2024 validated list.

Point‑Solution Fatigue, M&A, and Femtech’s Place in the Benefits Stack

Femtech doesn’t face the renewal reckoning in isolation. It competes inside a broader employer benefits landscape that is actively consolidating — and femtech’s typical positioning as a point solution makes it directly exposed to what analysts are now calling point solution fatigue.

The average large employer manages ten or more point solution vendor relationships. Multiple portals, multiple logins, fragmented data, no unified view of what’s working. Benefit leaders cannot tell executives what the return is across their vendor portfolio. The administrative burden alone is driving consolidation — over half of employers are expected to shift toward integrated engagement platforms by 2027.

The digital health M&A data reflects this: transaction volume increased 37 percent in 2025 compared to 2024, driven by platforms absorbing point solutions that couldn’t survive independent scrutiny.

The femtech companies most at risk in this wave are those that cannot demonstrate three things: measurable clinical outcomes, clean data that survives external review, and integration into a broader care architecture rather than functioning as a standalone app with a monthly invoice.

The Structural Problem Beneath the Commercial One

Every layer of this crisis points to the same root cause: engagement was assumed, not engineered.

The D2C model rewarded acquisition. The PMPM model rewarded contract signatures. Neither required femtech platforms to answer the harder question — in the case of a menopause‑focused benefits platform, what actually keeps a midlife woman showing up, progressing, and improving in ways her employer can measure and verify?

Enrollment is not engagement. Engagement is not outcomes. And in the current purchasing environment, outcomes are not outcomes unless they can survive independent scrutiny.

The platforms that will produce validated ROI in 2026 and 2027 are the ones that treated engagement as a clinical architecture problem, not a marketing one. They built predictive models for disengagement. They created intervention logic that fires before a user goes quiet. They connected behavioral signals to outcomes data in ways that hold up under third-party review.

Most femtech platforms didn’t build this. Not because their teams weren’t capable, but because the funding environment and contract structures didn’t require it. The requirement is arriving now, through the renewal conversation.

Where Metis Comes In

I spent 15 years inside enterprise Customer Success before moving into femtech and women’s health coaching. I’ve sat inside the platform — I understand where engagement architecture breaks down, why it gets deprioritized in the sprint toward contract signatures, and what it actually takes to build a retention system that generates defensible outcomes data.

I also understand, from the practitioner side, what meaningful engagement looks like for the specific populations femtech platforms serve — whether the focus is fertility, pregnancy, metabolic health, or menopause. In midlife care for example, women navigating hormonal transition are not passive consumers. They know when they’re being managed versus genuinely supported. Generic engagement sequences and low‑touch onboarding don’t just produce poor outcomes — they produce outcomes that are visibly poor to the user before they’re visible in the data.

That combination — fluency in the product, data, and operational constraints that shape engagement inside the platform, and fluency in what a sophisticated employer buyer will require at renewal — is the work Metis does on engagement architecture.

My gravitational pull is on the femtech company side. I spent 15 years in enterprise Customer Success and the last six years inside femtech companies as a health coach practitioner, which is how I’ve seen both the engagement problems and what it takes to measure real improvement. The mission behind Metis is to use that experience to help femtech teams design engagement that can be measured and defended in front of employer buyers, experienced as meaningful support by the women they serve, and reflected in stronger recurring revenue and retention. This is the work that has to happen before the renewal conversation — not during it, and not after a contract has already been lost. Now.

Metis is designed to work with a small number of women’s health technology platforms per year on a retained basis, with engagements structured around predictive engagement strategy, retention architecture, and outcomes measurement frameworks that hold up under both consumer and enterprise scrutiny.

If your platform is approaching a renewal cycle, the window to build what you need is open. It won’t stay that way.

Inquiries about Metis advisory work:
carla@metisfemtech.com | metisfemtech.com

Selected data points in this article draw on publicly available research on digital health utilization, employer benefits purchasing, outcomes‑based contracts, and digital health M&A, including work by Peterson Health Technology Institute, Business Group on Health, WTW, the Validation Institute, and leading women’s health vendors. A more detailed source list will be published in the Sources & Methodology section of the Metis Femtech Q2 2026 Intelligence Brief, “The Retention Reckoning,” scheduled for release in late June 2026.

Carla Moss is the founder of Metis Femtech Consultancy, a strategic advisory designed to help women’s health technology companies build AI-native customer success systems that sustain engagement, outcomes, and retention. She brings 15 years of enterprise Customer Success experience and 6+ years as a health coach practitioner inside digital health, combined with her work as a National Board-Certified Health and Wellness Coach specializing in midlife women’s health.

The Metis Engagement Architecture Design Process

A strategic advisory engagement designed to help women’s health technology companies build AI-native customer success systems that sustain engagement, outcomes, and retention.

And in many ways, that focus makes sense. The last decade of digital health innovation has been defined by what we can build—what data we can surface, what patterns we can detect, what experiences we can digitize. But as the category matures, a different constraint is beginning to surface.

The defining challenge in women’s health isn’t product innovation. It’s sustained engagement.

Women’s health is not a single moment problem. It is cyclical, longitudinal, and shaped by changing physiology, energy, and context over time. The experience of someone navigating perimenopause, for example, is not static from month to month—let alone year to year. Stress tolerance shifts. Cognitive capacity fluctuates. Priorities evolve. Identity itself often comes into question.

And yet, many digital health products are still designed around relatively stable patterns of use—assuming consistency in attention, motivation, and capacity. In practice, that assumption breaks down quickly.

Across digital health, engagement drop-off is well documented. Research consistently shows that a majority of users discontinue health apps within the first 30 to 90 days, with long-term retention remaining a persistent challenge across categories.

In women’s health, where meaningful engagement often spans years—not weeks—this gap becomes even more consequential.

My work sits at the intersection of women’s health and customer success—two domains that both depend on sustained engagement over time. One grounded in physiology, the other in systems and retention. From that vantage point, the disconnect becomes difficult to ignore.

The issue isn’t simply that engagement is low. It’s that engagement is being understood too narrowly. What works in short-term or transactional environments does not map cleanly onto long-term, physiology-driven experiences like women’s health. Reminders, nudges, and static content assume a level of consistency that many users simply don’t have access to—especially during periods of transition.

Engagement, in this context, is not simply a behavioral problem. It is shaped by something more dynamic—and less predictable.

As femtech continues to evolve, this gap will become more visible, not less. This challenge is already showing up at the company level. A majority of early-stage femtech ventures struggle to scale beyond initial funding, with industry estimates suggesting that as many as 70% fail to reach Series A—despite strong product innovation. The companies that succeed won’t just be those with better products. They will be the ones that can support users across changing capacity, shifting needs, and different stages of life—without assuming consistency where it doesn’t exist.

This is one of the central questions explored in the Q1 Metis Femtech Intelligence Brief. The brief examines how engagement is currently being approached across women’s health platforms—and where that approach begins to break down over time.

If you’re building or operating in femtech, you can access the full brief here:

Download the Q1-2026 Metis Femtech Intelligence Brief

Engagement isn’t a feature. It’s the foundation.